Aemetis (AMTX) Analysts See $-0.21 EPS; Heat Biologics (HTBX) Had 5 Bullish Analysts

October 11, 2017 - By Ellis Scott

Analysts expect Aemetis Inc (NASDAQ:AMTX) to report $-0.21 EPS on November, 13.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.21 EPS. After having $-0.30 EPS previously, Aemetis Inc’s analysts see -30.00% EPS growth. It closed at $0.84 lastly. It is down 50.79% since October 11, 2016 and is downtrending. It has underperformed by 67.49% the S&P500.

Among 5 analysts covering Heat Biologics (NASDAQ:HTBX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heat Biologics had 7 analyst reports since September 1, 2015 according to SRatingsIntel. On Thursday, February 4 the stock rating was downgraded by Cantor Fitzgerald to “Speculative Buy”. On Friday, January 8 the stock rating was initiated by Noble Financial with “Buy”. The company was maintained on Thursday, September 3 by H.C. Wainwright. The rating was maintained by Noble Financial on Wednesday, June 7 with “Buy”. Cantor Fitzgerald maintained Heat Biologics Inc (NASDAQ:HTBX) rating on Tuesday, September 1. Cantor Fitzgerald has “Buy” rating and $18 target. Griffin initiated Heat Biologics Inc (NASDAQ:HTBX) on Tuesday, September 12 with “Buy” rating. On Monday, June 20 the stock rating was initiated by Roth Capital with “Buy”. See Heat Biologics Inc (NASDAQ:HTBX) latest ratings:




12/09/2017 Broker: Griffin Rating: Buy New Target: $2.25 Initiate
07/06/2017 Broker: Noble Financial Rating: Buy Maintain

Aemetis, Inc. is an international renewable fuels and biochemicals company. The company has market cap of $16.65 million. The Firm is focused on the production of fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum products by conversion of first-generation ethanol and biodiesel plants into biorefineries. It currently has negative earnings. The Company’s divisions include North America and India.

Heat Biologics, Inc. is a development-stage firm focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The company has market cap of $25.62 million. The Firm is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). It currently has negative earnings. Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: